Previous 10 | Next 10 |
Russia’s invasion of Ukraine, the biggest conventional military attack in Europe since World War II, has wide-ranging implications for economies and markets around the world. Disruptions from this war and the higher energy prices that result could significantly dampen Europe...
We are initiating with CTI BioPharma with a buy rating with a TP of USD 7.6 if pacritinib is approved. We opine that CTI BioPharma's current set-up represents an attractive risk-reward scenario with ~50% potential downside (around cash value of $1/share) and ~320% potential upside (bu...
Retail investors continue to favor growth names over value and lean to tech, according to Goldman Sachs' new report on retail buy and sell activity. "We estimate retail investors were net buyers of $7 billion in Russell 3000 (NYSEARCA:IWV) stocks since the volatility spike on 24-Jan-2022," Jo...
Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This report optimizes tradi...
The subsector with the best value and quality scores is pharmaceutical/biotechnology. Life science tools and healthcare equipment are the most overvalued. Fast facts on IDNA. A list of cheap stocks. For further details see: IDNA: Healthcare Dashboard For February
ETFs are a great way to approach broad plays that focus on sector allocation rather than intra-sector allocation where quality of decisions results in more marginal benefits. We think that the theme for the year is inflation and that opinions on this will shift the markets more than m...
The macroeconomic backdrop of Fed interest rate hikes is rapidly deflating overvalued technology companies and "crypto-collectibles." We expect the technology sector to underperform value and biotech. After the sell-off, biotech companies' valuation is close to the 2018 level even tho...
No matter how long is the time you dedicate to look at/hold AbbVie, it's a "movie" with a happy ending, with a second-to-none acting performance. In spite of near-future growth concerns, and even if the stock might be (technically/optically) looking fully valued, we believe that there...
The private sector balance decreased by over -$102+ billion in January 2022, due to a federal government surplus withdrawing financial assets from the private sector. Credit creation from commercial banks was weaker at $87B+. The seasonal pattern is down until early-to-mid March a...
Since the acquisition of Alexion was completed, we were watching AstraZeneca from the sidelines. Holding but not taking any further action. Q4/FY 2021 earnings are marking a turning point for the company, for its future, for its dividend, and (consequently) for us. This has been nothi...
News, Short Squeeze, Breakout and More Instantly...
iShares Biotechnology ETF Company Name:
IBB Stock Symbol:
NASDAQ Market:
2024-07-19 00:34:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-06-28 22:58:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...